Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH,

Jacene H, Bushnell D (2017) Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors.

N Engl J Med 376(2):125–135

Targeted Alpha Therapy Working Group (2018) Targeted alpha therapy, an emerging class of

cancer agents: a review. JAMA Oncol 4(12):1765–1772

Ulaner GA, Jacene HA, Parihar AS, Groheux D (2021) Evidence based best practices: 18F-FDG

PET staging of newly diagnosed breast cancer. Clin Nucl Med 46(7):569–570. https://journals.

lww.com/nuclearmed/Fulltext/2021/07000/Evidence_Based_Best_Practices__18F_FDG_

PET_Staging.7.aspx. Ahead of Print

Vadi SK, Mittal BR, Sood A, Singh G, Bal A, Parihar AS, Bhattacharya A, Basher RK, Kapoor R

(2019) Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence

of male breast cancer. Nucl Med Commun 40(1):63–72

Vahidfar N, Fallahpoor M, Farzanehfar S, Divband G, Ahmadzadehfar H (2019) Historical review

of pharmacological development and dosimetry of PSMA-based theranostics for prostate

cancer. J Radioanal Nucl Chem 322:237–248. https://doi.org/10.1007/s10967-019-06800-6

Vander Heiden MG, DeBerardinis RJ (2017) Understanding the intersections between metabolism

and cancer biology. Cell 168(4):657–669

Watts A, Singh B, Basher R, Singh H, Bal A, Kapoor R, Arora SK, Wester HJ, Mittal BR, Behera D

(2017) 68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung

carcinoma than in non-small cell variant. Eur J Nucl Med Mol Imaging (44):909–910

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D,

Hawkins R, Shulkin BL, Jackson H (2015) 131I-metaiodobenzylguanidine with intensive

chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new

approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant

21(4):673–681

Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G,

Schmidt-Wolf I, Lingohr P, Fischer S, Kristiansen G, Essler M (2017a) A step-by-step clinical

approach for the management of neuroendocrine tumours. Horm Metab Res 49(2):77–85

Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H

(2017b) The impact of repeated cycles of radioligand therapy using [177 Lu] Lu-PSMA-617 on

renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med

Mol Imaging 44(9):1473–1479

Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M,

Ahmadzadehfar H (2017c) Safety of multiple repeated cycles of 177 Lu-octreotate in patients

with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging 44(7):1207–1214

Zhang J, Li D, Niu G, Baum R, Zhu Z, Chen X (2020) First-in-human study of a64Cu-labeled long-

acting integrin αvβ3 targeting molecule64Cu-NOTA-EB-RGD in healthy volunteers and GBM

patients. J Nucl Med 61(Suppl 1):349

Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK (2015) Different

outcomes

for

relapsed

versus

refractory

neuroblastoma

after

therapy

with

131I-

metaiodobenzylguanidine (131I-MIBG). Eur J Cancer 51(16):2465–2472

Zlotnik A, Burkhardt AM, Homey B (2011) Homeostatic chemokine receptors and organ-specific

metastasis. Nat Rev Immunol 11(9):597–606

110

B. Singh et al.